[go: up one dir, main page]

PE20140962A1 - Una formulacion farmaceutica solida - Google Patents

Una formulacion farmaceutica solida

Info

Publication number
PE20140962A1
PE20140962A1 PE2014000196A PE2014000196A PE20140962A1 PE 20140962 A1 PE20140962 A1 PE 20140962A1 PE 2014000196 A PE2014000196 A PE 2014000196A PE 2014000196 A PE2014000196 A PE 2014000196A PE 20140962 A1 PE20140962 A1 PE 20140962A1
Authority
PE
Peru
Prior art keywords
formulation
pharmaceutical formulation
solid pharmaceutical
starch
weight
Prior art date
Application number
PE2014000196A
Other languages
English (en)
Inventor
Tadashi Mukai
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40847022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140962(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of PE20140962A1 publication Critical patent/PE20140962A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA SOLIDA QUE COMPRENDE: A) CILOSTAZOL; B) ALMIDON PREGELATINIZADO TAL COMO ALMIDON DE MAIZ, ALMIDON DE TRIGO, ALMIDON DE PAPA, ENTRE OTROS, EN UNA CANTIDAD DE 10 A 90% EN PESO BASADO EN EL PESO TOTAL DE LA FORMULACION; C) COPOLIMERO DE ACIDO METACRILICO S, Y D) ACIDO CITRICO EN UNA CANTIDAD DE 0.5 A 5% EN PESO BASADO EN EL PESO DEL TOTAL DE LA FORMULACION. DICHA FORMULACION SE ENCUENTRA EN LA FORMA DE PARTICULAS, GRANULOS O POLVOS. SE REFIERE ADEMAS A UN METODO PARA LA PREPARACION DE LA FORMULACION FARMACEUTICA
PE2014000196A 2008-05-15 2009-05-12 Una formulacion farmaceutica solida PE20140962A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008128259 2008-05-15

Publications (1)

Publication Number Publication Date
PE20140962A1 true PE20140962A1 (es) 2014-08-15

Family

ID=40847022

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2009000651A PE20091900A1 (es) 2008-05-15 2009-05-12 Una formulacion farmaceutica solida
PE2014000196A PE20140962A1 (es) 2008-05-15 2009-05-12 Una formulacion farmaceutica solida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2009000651A PE20091900A1 (es) 2008-05-15 2009-05-12 Una formulacion farmaceutica solida

Country Status (31)

Country Link
US (1) US20110091535A1 (es)
EP (1) EP2273981B1 (es)
JP (1) JP5552434B2 (es)
KR (1) KR101585280B1 (es)
CN (2) CN102119024A (es)
AR (1) AR071706A1 (es)
AU (1) AU2009247156B2 (es)
BR (1) BRPI0912656A2 (es)
CA (1) CA2722244C (es)
CL (1) CL2009001183A1 (es)
CO (1) CO6321223A2 (es)
CY (1) CY1115955T1 (es)
DK (1) DK2273981T3 (es)
EA (1) EA022712B1 (es)
EC (1) ECSP10010683A (es)
ES (1) ES2524261T3 (es)
HR (1) HRP20141134T1 (es)
IL (1) IL208788A (es)
MX (1) MX2010012432A (es)
MY (1) MY153109A (es)
NZ (1) NZ588794A (es)
PE (2) PE20091900A1 (es)
PL (1) PL2273981T3 (es)
PT (1) PT2273981E (es)
RS (1) RS53775B1 (es)
SG (1) SG190643A1 (es)
SI (1) SI2273981T1 (es)
TW (1) TWI501789B (es)
UA (1) UA102547C2 (es)
WO (1) WO2009139504A2 (es)
ZA (1) ZA201008115B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101282847B1 (ko) * 2011-07-27 2013-07-05 조선대학교산학협력단 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물
TWI615157B (zh) 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
CN103920156B (zh) * 2014-04-04 2016-06-01 成都科特包衣技术有限公司 一种口服给药肠道定位释药薄膜包衣预混辅料及其制备方法
CN106511313B (zh) * 2016-10-21 2019-06-07 浙江为康制药有限公司 西洛他唑缓释胶囊组合物及其制备方法
EP3409294A1 (en) 2017-06-01 2018-12-05 Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. Tablets containing cilostazol of specific particle size distribution
JP7640453B2 (ja) * 2019-04-25 2025-03-05 富士製薬工業株式会社 医薬製剤およびその製造方法
WO2025133928A2 (en) * 2023-12-19 2025-06-26 Angelini Pharma S.P.A. Pharmaceutical matrices for prolonged drug release

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
US7138143B1 (en) * 1999-09-30 2006-11-21 Otsuka Pharmaceutical Company, Limited Coated preparation soluble in the lower digestive tract
JP4637338B2 (ja) * 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
JP2002193792A (ja) * 2000-12-25 2002-07-10 Lion Corp フィルムコーティング錠剤及びエロージョン防止組成物
WO2004039361A1 (en) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
JP2006512359A (ja) * 2002-12-20 2006-04-13 ファイザー・プロダクツ・インク ＣＥＴＰ阻害薬及びＨＭＧ−ＣｏＡ還元酵素阻害薬を含有する剤形
WO2005023225A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Cilostazol adsorbate
US20050255155A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Modified release cilostazol compositions
TWI338583B (en) * 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
JP5112619B2 (ja) * 2004-05-20 2013-01-09 大塚製薬株式会社 固形医薬製剤
WO2007072495A2 (en) * 2005-11-03 2007-06-28 Sun Pharmaceutical Industries Limited Coated tablets having prolonged gastric retention
WO2007105229A1 (en) * 2006-03-14 2007-09-20 Panacea Biotec Ltd. Controlled release pharmaceutical composition and process thereof
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
JP2010508266A (ja) * 2006-10-30 2010-03-18 ハナル ファーマシューティカル カンパニー リミテッド チアジド系化合物およびアンジオテンシン−ｉｉ−受容体遮断剤を含む放出性が制御された薬学的組成物
KR20150064227A (ko) * 2007-10-19 2015-06-10 오츠카 세이야쿠 가부시키가이샤 매트릭스형 의약 고형 제제
WO2009118764A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Pharmaceutical composition comprising diclofenac and paracetamol

Also Published As

Publication number Publication date
AR071706A1 (es) 2010-07-07
JP5552434B2 (ja) 2014-07-16
AU2009247156A1 (en) 2009-11-19
KR20110007255A (ko) 2011-01-21
TWI501789B (zh) 2015-10-01
KR101585280B1 (ko) 2016-01-13
AU2009247156B2 (en) 2013-10-24
IL208788A (en) 2016-05-31
MY153109A (en) 2014-12-31
CO6321223A2 (es) 2011-09-20
CA2722244C (en) 2016-09-13
BRPI0912656A2 (pt) 2016-01-26
CL2009001183A1 (es) 2010-06-18
DK2273981T3 (en) 2014-11-24
ZA201008115B (en) 2012-01-25
SG190643A1 (en) 2013-06-28
CY1115955T1 (el) 2017-01-25
SI2273981T1 (sl) 2015-01-30
EP2273981A2 (en) 2011-01-19
NZ588794A (en) 2012-07-27
HK1149497A1 (en) 2011-10-07
CN102119024A (zh) 2011-07-06
EA201071309A1 (ru) 2011-06-30
TW201000152A (en) 2010-01-01
PT2273981E (pt) 2015-01-02
WO2009139504A3 (en) 2010-09-30
CN104971037A (zh) 2015-10-14
PE20091900A1 (es) 2009-12-31
CA2722244A1 (en) 2009-11-19
PL2273981T3 (pl) 2015-04-30
HRP20141134T1 (hr) 2015-01-30
ECSP10010683A (es) 2011-01-31
JP2011520774A (ja) 2011-07-21
EP2273981B1 (en) 2014-11-05
UA102547C2 (uk) 2013-07-25
RS53775B1 (sr) 2015-06-30
WO2009139504A2 (en) 2009-11-19
ES2524261T3 (es) 2014-12-04
US20110091535A1 (en) 2011-04-21
MX2010012432A (es) 2010-12-06
EA022712B1 (ru) 2016-02-29
IL208788A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
PE20140962A1 (es) Una formulacion farmaceutica solida
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
MX357914B (es) Composiciones y articulos para el cuidado personal.
MY177741A (en) Pharmaceutical compositions compring 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one-lactate monohydrate.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12015500301B1 (en) A novel formulation of diclofenac
WO2013175221A3 (en) Composition
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
GT201300309A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
MY168413A (en) Amino-substituted imidazopyridazines
MX351930B (es) Una formulacion novedosa de indometacina.
MX360019B (es) Una formulación novedosa de metaxalona.
PH12016500746B1 (en) A novel formulation of meloxicam
AR053803A1 (es) Uso de acido pinolenico
EA201100316A1 (ru) Новая крахмальная композиция и способ производства выпеченных изделий
AR079639A1 (es) Composicion de pasta de dientes anti-erosiva
PH12014502512A1 (en) Topical pharmaceutical compositions comprising terbinafine and urea
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
PH12016500054A1 (en) Substituted pyrazolo-pyridinamines
CY1109865T1 (el) Συνθεσεις βαλσαρτανης
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX356373B (es) Composiciones que comprenden un agente antibacterial y tazobactam.
PH12018501876A1 (en) Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
CL2009000965A1 (es) Tableta oral compuesta por un compuesto i que comprende un 10 a 20% en peso de la tableta o su sal farmaceuticamente aceptable, que comprende ademas de un agente aglutinante, un desintegrante, un diluyente; proceso de preparacion de la tableta; y su uso en el tratamiento de vih y enfermedades inflamatorias.

Legal Events

Date Code Title Description
FC Refusal